Vector BioMed

Cambridge, MA
AAV Lentiviral
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Vector BioMed

Signal Score
59.0/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Cambridge, MA
Modalities
AAV, Lentiviral
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Vector BioMed

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Cambridge, MA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Cambridge, MA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Cambridge, MA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

FDA 483 Findings 4 observations · 2025-08-05 → 2025-08-05 ?

By subsystem

  • Other 2 (50.0%)
  • Documentation & Records 1 (25.0%)
  • CAPA 1 (25.0%)

By severity

  • 3 — Moderate: 1
  • 2 — Minor: 3
  • Repeat observations: 0

Most severe findings

  • Moderate (3) CAPA 2025-08-05 21 CFR 820.100(a)
    Lack of or inadequate procedures

    "Procedures for corrective and preventive action have not been adequately established."

  • Minor (2) Other 2025-08-05 21 CFR 803.50(a)(1)
    Report of Death or Serious Injury

    "An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have caused or contributed to a death or serious injury."

  • Minor (2) Other 2025-08-05 21 CFR 806.10(a)(1)
    Report of risk to health

    "A correction or removal, conducted to reduce a risk to health posed by a device, was not reported in writing to FDA."

About this data →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral
Genezen
Indianapolis, IN · Lexington, MA
Signal Score: 70.7
AAV, Lentiviral
uBriGene Biosciences
Shanghai, CN · Boston, MA
Signal Score: 60.5
AAV, Lentiviral, Plasmid
VintaBio
Cambridge, MA
Signal Score: 59.0
AAV, Lentiviral
ElevateBio BaseCamp
Waltham, MA
Signal Score: 59.0
AAV, Lentiviral, CAR-T